Mesenchymal Stem Cells News and Research

RSS

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Human stem cells administered intravenously can restore alveolar epithelial tissue to a normal function in a novel ex vivo perfused human lung after E. coli endotoxin-induced acute lung injury, according to research from the University of California San Francisco.

18 May 2010

Calcium deficiency may make people more prone to osteoporosis, obesity in later life: Study

There's no denying that people need calcium for strong, healthy bones. But new research from North Carolina State University suggests that not getting enough calcium in the earliest days of life could have a more profound, lifelong impact on bone health and perhaps even obesity than previously thought.

14 May 2010

Advances in combination adult stem cell treatment for acute myocardial infarction presented at SCAI

This week, TCA Cellular Therapy's Medical Director Gabriel Lasala, M.D. presents advances in a proprietary combination adult stem cell treatment for acute myocardial infarction at the Society for Cardiovascular Angiography and Interventions (SCAI) scientific conference in San Diego.

7 May 2010

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Osiris Therapeutics, Inc. today announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. The FDA instituted the Orphan Drug Act to promote the development of treatments for underserved patient populations. To be eligible for Orphan Drug designation, the treatment must target a disease that affects fewer than 200,000 new patients per year in the United States.

5 May 2010

Urging school children to pay attention to dairy intake may be too late to optimize their bone health: Research

We all know that eating a calcium-rich diet is important for keeping our bones healthy and strong. This concept is clearly on display in any elementary school cafeteria where the walls are decorated with colorful posters with celebrity icons encouraging children to make sure they drink milk every day.

26 Apr 2010

Role of lactate in breast cancer development to be showcased at AACR 2010

Does lactate play a role in the metabolic fate of cancer cells? Researchers from The Cancer Institute of New Jersey are in Washington, D.C., this week for the 101st Annual Meeting of the American Association for Cancer Research to share their findings on what role this common energy byproduct in the body plays in the development of breast cancer cells and surrounding connective tissue.

19 Apr 2010

Menstrual stem cells may help in treatment of stroke and central nervous system disorders

Cryo-Cell International, Inc. today announced results of a study published this month in the cover article of Stem Cells and Development showing that stem cells found in menstrual blood may one day be a potential source for stem cell therapies in stroke and other central nervous system disorders.

5 Apr 2010

$Notch pathway could aid treatment of osteoporosis, fractures and arthritis$

Notch pathway could aid treatment of osteoporosis, fractures and arthritis

Scientists seeking new ways to fight maladies ranging from arthritis and osteoporosis to broken bones that won't heal have cleared a formidable hurdle, pinpointing and controlling a key molecular player to keep stem cells in a sort of extended infancy.

31 Mar 2010

Stemedica files IND for trial using allogeneic mesenchymal bone marrow cells in patients with ischemic stroke

Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.

19 Mar 2010

ESWT applied with SANUWAVE’s Ossatron device results in 80% healing rate of nonunions of the tibia

SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, today announced that a journal article titled Extracorporeal Shock Wave Therapy for Nonunion of the Tibia, was published in the March 2010 issue of the Journal of Orthopedic Trauma.

10 Mar 2010

MS Awareness Week: Time for nation to go orange and move it to end MS

MS Awareness Week March 8-14 is the time for the nation to go orange and move it to end multiple sclerosis, a disease where someone is newly diagnosed every hour of every day. Supported by a Congressional resolution, this year MS Awareness Week and the state of MS research aptly coincide. Move it to create a world free of MS!

8 Mar 2010

Recipients for 2010 Scholar Awards announced

The American Society of Hematology announces the 2010 recipients of its Scholar Awards. The program is designed to support hematologists who have chosen a career in research by providing partial salary or other support during that critical period required for completion of training and achievement of status as an independent investigator.

5 Mar 2010

Pre-clinical study of Cardio3 BioSciences' proprietary C-Cath catheter announced

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today promising results in a pre-clinical study of its proprietary C-Cath(R) catheter which is under development to administer a range of bio-therapeutics to the heart. C-Cath is designed to take into account organ tissue structure and properties to maximize patients' safety, improve performance and increase user confidence during the injection procedure.

2 Mar 2010

Study demonstrates Prochymal treamtent is safe for cardiac patients

“Patients receiving Prochymal did better than those receiving only standard-of-care,” said Dr. Hare, lead author of the JACC publication.

25 Feb 2010

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is extremely pleased to announce that it has entered into a collaborative agreement with Hadassah Medical Center to conduct its ALS clinical trials at the Hadassah Ein Kerem Hospital.

22 Feb 2010

Study reveals people with anorexia nervosa have increased fat content in their bone marrow

People with anorexia nervosa, paradoxically, have strikingly high levels of fat within their bone marrow, report researchers at Children's Hospital Boston. Their findings, based on MRI imaging of the knees of 20 girls with anorexia and 20 healthy girls of the same age, appear in the February issue of the Journal of Bone and Mineral Research.

9 Feb 2010

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.

23 Dec 2009

New findings may help restore vision in patients with corneal injury

Winston Whei-Yang Kao, PhD, professor of ophthalmology, along with other researchers in UC's ophthalmology department found that transplanting human umbilical mesenchymal stem cells into mouse models that lack the protein lumican restored the transparency of cloudy and thin corneas.

9 Dec 2009

University of Texas launches phase II clinical trial to test stem-cell-based therapy on injured heart muscle

The second phase of a clinical trial testing a new stem-cell-based therapy on injured heart muscle has been launched by researchers at The University of Texas Medical School at Houston. It is the only study site in the Texas Medical Center.